The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 08, 2022
Filed:
Sep. 11, 2015
Applicant:
Memorial Sloan-kettering Cancer Center, New York, NY (US);
Inventors:
Victor D. Fedorov, New York, NY (US);
Michel Sadelain, New York, NY (US);
Assignee:
MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/40 (2006.01); A61K 39/00 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 14/73 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/00117 (2018.08); A61K 39/00118 (2018.08); A61K 39/001102 (2018.08); A61K 39/001106 (2018.08); A61K 39/001109 (2018.08); A61K 39/001112 (2018.08); A61K 39/001113 (2018.08); A61K 39/001114 (2018.08); A61K 39/001117 (2018.08); A61K 39/001119 (2018.08); A61K 39/001124 (2018.08); A61K 39/001126 (2018.08); A61K 39/001128 (2018.08); A61K 39/001129 (2018.08); A61K 39/001153 (2018.08); A61K 39/001157 (2018.08); A61K 39/001166 (2018.08); A61K 39/001168 (2018.08); A61K 39/001171 (2018.08); A61K 39/001182 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001193 (2018.08); A61K 39/001195 (2018.08); C07K 14/7051 (2013.01); C07K 14/70514 (2013.01); C07K 14/70517 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01);
Abstract
The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.